Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in early trial

NCT ID NCT05911841

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called LY3454738 in adults with moderate-to-severe atopic dermatitis (eczema). The goal was to see if it could improve skin symptoms like redness and itching. The trial included 234 participants and was stopped early. Results may help understand if this drug can control the disease long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

234 people

The number who actually took part.

Started

Jun 2023

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Are candidates for systemic therapy. ISA specific: * Have moderate-to-severe AD, defined as meeting all of the following criteria, at the first dosing visit: * EASI score greater than or equal to (≥)16 * vIGA-AD score ≥3, and * ≥10% of BSA involvement (per EASI BSA). * Have applied at least 1 emollient every day for at least 2 weeks before the day of the first dose of study intervention in this ISA and agree to daily use of at least 1 emollient continuously throughout the study. Exclusion Criteria: ISA specific: * Have, in the screening period, any of the skin conditions, infections, or medical conditions listed under master IMMB. * Are currently being treated with topical or systemic therapy * Recent treatment with experimental (biologics and/or small molecules) - doesn't apply for subset of participants who must have been exposed to biologics and/or small molecules.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • "DERMED" Centrum Medyczne Sp. z o.o.

    Lodz, Łódź Voivodeship, 90-265, Poland

  • ActivMed Practices & Research, Inc.

    Portsmouth, New Hampshire, 03801, United States

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 212000, China

  • Allergo-Derm Bakos Kft

    Szolnok, Jász-Nagykun-Szolnok, 5000, Hungary

  • Allergy and Asthma Specialist

    Owensboro, Kentucky, 42301, United States

  • Alpha Recherche Clinique

    Québec, G2J 0C4, Canada

  • Arkansas Research Trials

    North Little Rock, Arkansas, 72217, United States

  • CCA Medical Research

    Ajax, Ontario, L1S 7K8, Canada

  • Center for Clinical Studies

    Webster, Texas, 77598, United States

  • Centro de Atención en Enfermedades Inflamatorias CATEI

    Guadalajara, Jalisco, 44630, Mexico

  • Centro de Investigacion Clinica de Oaxaca

    Oaxaca City, 68020, Mexico

  • Centrum Badan Klinicznych PI-House sp. z o.o.

    Gdansk, Pomeranian Voivodeship, 80-546, Poland

  • Chang Gung Medical Foundation-Linkou Branch

    Taoyuan, 333, Taiwan

  • Chang Gung Memorial Hospital at Kaohsiung

    Kaohsiung Niao Sung Dist, Kaohsiung, 83301, Taiwan

  • Chung Shan Medical University Hospital

    Taichung, Taichung, 402, Taiwan

  • Chung-Ang University Hospital

    Dongjak-gu, Seoul-teukbyeolsi [Seoul], 06973, South Korea

  • Conquest Research

    Winter Park, Florida, 32789, United States

  • Cryptex Investigación Clínica S.A. de C.V.

    Cuauhtémoc, Ciudad de México, Mexico City, 06100, Mexico

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, 4032, Hungary

  • DermDox Centers for Dermatology

    Camp Hill, Pennsylvania, 17011, United States

  • Dermatology Research Associates

    Los Angeles, California, 90045, United States

  • Dermatology and Ophthalmology Kume Clinic

    Sakai, Osaka, 593-8324, Japan

  • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak

    Lodz, Łódź Voivodeship, 90-436, Poland

  • Diamond Clinic

    Krakow, Lesser Poland Voivodeship, 31-559, Poland

  • Encore Medical Research

    Hollywood, Florida, 33024, United States

  • Eukarya PharmaSite

    Monterrey, Nuevo León, 64718, Mexico

  • FACET Dermatology

    Toronto, Ontario, M4E 1R7, Canada

  • Hallym University Kangnam Sacred Heart Hospital

    Seoul, Seoul-teukbyeolsi [Seoul], 07441, South Korea

  • Hamilton Allergy

    Hamilton, Ontario, L8S 1G5, Canada

  • Huashan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200040, China

  • Johnson Dermatology

    Fort Smith, Arkansas, 72916, United States

  • Korea University Ansan Hospital

    Ansan-si, Kyǒnggi-do, 15355, South Korea

  • Lynderm Research Inc.

    Markham, Ontario, L3P 1X3, Canada

  • MICS Centrum Medyczne Warszawa

    Warsaw, Masovian Voivodeship, 00-874, Poland

  • Markusovszky Egyetemi Oktatokorhaz

    Szombathely, Vas County, 9700, Hungary

  • Medmare Bt

    Veszprém, Veszprém City, 8200, Hungary

  • Metropolitan Dermatology - Clark

    Kenilworth, New Jersey, 07033, United States

  • National Medical Center

    Seoul, Seoul-teukbyeolsi [Seoul], 01812, South Korea

  • National Taiwan University Hospital

    Taipei, 10002, Taiwan

  • National Taiwan University Hospital - Hsinchu branch

    Hsinchu, 300, Taiwan

  • New Taipei Municipal TuCheng Hospital

    New Taipei City, New Taipei, 236, Taiwan

  • Nihonbashi Sakura Clinic

    Chuo-ku, Tokyo, 103-0025, Japan

  • Nomura Dermatology Clinic

    Yokohama, Kanagawa, 221-0825, Japan

  • Oregon Dermatology and Research Center

    Portland, Oregon, 97210, United States

  • Progressive Clinical Research

    San Antonio, Texas, 78213, United States

  • Pusan National University Hospital

    Busan, Pusan-Kwangyǒkshi, 49241, South Korea

  • RM Pharma Specialists

    Mexico City, Mexico City, 03100, Mexico

  • Rejuvenation Dermatology

    Calgary, Alberta, T2W 4X9, Canada

  • Rejuvenation Dermatology

    Edmonton, Alberta, T5J 3S9, Canada

  • Renmin Hospital of Wuhan University

    Wuhan, 430060, China

  • Revival Research Institute, LLC

    Troy, Michigan, 48084, United States

  • Scientia Investigacion Clinica S.C.

    Chihuahua City, 31207, Mexico

  • Somogy Megyei Kaposi Mór Oktató Kórház

    Kaposvár, Somogy County, 7400, Hungary

  • Specderm Poznanska

    Bialystok, Podlaskie Voivodeship, 15-375, Poland

  • Tachikawa Dermatology Clinic

    Tachikawa, Tokyo, 190-0023, Japan

  • Taipei Medical University Shuang Ho Hospital

    New Taipei City, 235, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • Takagi Dermatological Clinic

    Obihiro-shi, Hokkaido, 080-0013, Japan

  • The Catholic University of Korea, Incheon St. Mary's Hospital

    Bupyeong-gu, Incheon-gwangyeoksi [Incheon], 21431, South Korea

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, 710061, China

  • Tri-Service General Hospital

    Taipei City, Taipei, 114, Taiwan

  • Trials in Medicine

    Mexico City, Mexico City, 06700, Mexico

  • Wiseman Dermatology Research Inc.

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Xiangya Hospital Central South University

    Changsha, Hunan, 410008, China

  • Yasumoto Dermatology Clinic

    Chikushino-shi, Fukuoka, 818-0083, Japan

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.